

Table S1. Characteristics of the population with antipsychotic use

	First generation antipsychotics					Second generation antipsychotics						
	Chlorpromazine	Levomepromazine	Perphenazine	Haloperidol	Sulpiride	Olanzapine	Quetiapine	Risperidone	Aripiprazole	Paliperidone	Blonanserin	Perospirone
Claims, n	79,205	103,554	22,657	92,221	32,771	226,302	170,552	279,014	307,559	22,191	46,318	43,298
Users, n	8,781	8,134	2,716	12,036	4,166	18,709	13,329	22,239	26,787	1,756	3,926	3,617
Incident users, n	5,785	4,861	1,779	8,593	2,860	12,359	8,646	13,655	19,307	1,223	2,647	2,287
Male, n (%)	3,092 (53.4)	2,290 (47.1)	816 (45.9)	4,934 (57.4)	1,907 (66.7)	6,259 (50.6)	4,099 (47.4)	7,142 (52.3)	10,375 (53.7)	506 (41.4)	1,036 (39.1)	896 (39.2)
Diagnosis of schizophrenia, n (%)	2,183 (37.7)	2,904 (59.7)	637 (35.8)	3,129 (36.4)	540 (18.9)	8,783 (71.1)	7,458 (86.3)	10,424 (76.3)	11,728 (60.7)	1,196 (97.8)	2,564 (96.9)	2,028 (88.7)
Age, years, n (%)												
<20	961 (16.6)	486 (10.0)	175 (9.8)	649 (7.6)	151 (5.3)	1,175 (9.5)	790 (9.1)	3,778 (27.7)	3,530 (18.3)	186 (15.2)	368 (13.9)	251 (11.0)
20-39	1,950 (33.7)	2,166 (44.6)	812 (45.6)	1,947 (22.7)	1,331 (46.5)	5,560 (45.0)	3,754 (43.4)	4,501 (33.0)	8,346 (43.2)	562 (46.0)	1,222 (46.2)	1,075 (47.0)
40-59	2,243 (38.8)	1,943 (40.0)	677 (38.1)	3,832 (44.6)	1,220 (42.7)	4,902 (39.7)	3,382 (39.1)	4,047 (29.6)	6,810 (35.3)	419 (34.3)	934 (35.3)	831 (36.3)
60-75	631 (10.9)	266 (5.5)	115 (6.5)	2,165 (25.2)	158 (5.5)	722 (5.8)	720 (8.3)	1,329 (9.7)	621 (3.2)	56 (4.6)	123 (4.6)	130 (5.7)
Median [range]	39 [0-75]	38 [2-75]	37 [1-75]	49 [3-75]	39 [10-75]	38 [5-75]	38 [2-75]	33 [1-75]	35 [2-75]	34 [5-75]	35 [3-75]	36 [6-75]

Incident users: number of patients who received their first prescription for antipsychotics

Diagnosis of schizophrenia: number of patients who were diagnosed of schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (ICD-10 code: F20-F29) on incident date